VP3.15

• Description :

  VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE) 7- glycogen synthase kinase (GSK) 3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) [1].

• UNSPSC :

  12352005

• Target :

  GSK-3; Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/vp3-15.html

• Solubility :

  10 mM in DMSO

• Smiles :

  N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1

• Molecular Formula :

  C20H22N4OS

• Molecular Weight :

  366.48

• References & Citations :

  [1]Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDE7

• Citation 01 :

  J Biol Chem. 2023 Aug;299 (8) :104991.|J Biol Chem. 2025 Jan 27:108244.|Pennsylvania State University. 2025.

• CAS Number :

  [1281681-54-6]